Tomorrow Access confirmed that Freenome acquired a new patent for a single stool sample test for colorectal cancer, which was granted U.S. FDA approval in July 2026, with the company holding the exclusive right to sell the test alone.

Tomorrow Access is a Silicon Valley-based consulting firm bridging Japan and the US. Founded by Ken Sobajima — recognized in the Global Corporate Venturing (GCV) Top 50 Emerging Leaders out of 20,000+ CVC professionals worldwide — we bring 25+ years of business development experience, 20+ portfolio investments, and 30B+ JPY in business development track record. Our services: ・Business Strategy Consulting for Japanese enterprises expanding into the US ・Spot Consulting for time-sensitive market questions ・Startup Mentoring for Japanese founders entering Silicon Valley ・01 Expert Pitch — our flagship webinar series (30 sessions, 6,000+ participants) ・Trend Intelligence newsletter (3,000+ subscribers) We work hands-on with corporate innovation teams, CVCs, and startups to help them build their own path across borders.